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Abstract 
The resistance of residual cancer cells after oncological resection to adjuvant chemoradio-
therapies results in both high recurrence rates and high non-specific tissue toxicity, thus 
preventing the successful treatment of such cancers as head and neck squamous cell carci-
noma (HNSCC). The patients’ survival rate and quality of life therefore depend upon the ef-
ficacy, selectivity and low non-specific toxicity of the adjuvant treatment. We report a novel, 
theranostic in vivo technology that unites both the acoustic diagnostics and guided intracellular 
delivery of anti-tumor drug (liposome-encapsulated doxorubicin, Doxil) in one rapid process, 
namely a pulsed laser-activated plasmonic nanobubble (PNB). HNSCC-bearing mice were 
treated with gold nanoparticle conjugates, Doxil, and single near-infrared laser pulses of low 
energy. Tumor-specific clusters of gold nanoparticles (solid gold spheres) converted the op-
tical pulses into localized PNBs. The acoustic signals of the PNB detected the tumor with high 
specificity and sensitivity. The mechanical impact of the PNB, co-localized with Doxil lipo-
somes, selectively ejected the drug into the cytoplasm of cancer cells. Cancer cell-specific 
generation of PNBs and their intracellular co-localization with Doxil improved the in vivo 
therapeutic efficacy from 5-7% for administration of only Doxil or PNBs alone to 90% thus 
demonstrating the synergistic therapeutic effect of the PNB-based intracellular drug release. 
This mechanism also reduced the non-specific toxicity of Doxil below a detectable level and 
the treatment time to less than one minute. Thus PNBs combine highly sensitive diagnosis, 
overcome drug resistance and minimize non-specific toxicity in a single rapid theranostic 
procedure for intra-operative treatment. 
Key words: plasmonic nanobubble, cancer cell,  
INTRODUCTION 
One of the major limitations of traditional 
treatments of cancers is the inability to surgically re-
sect a tumor completely without having to remove 
large areas of normal tissue that serve critical func-
tions. Residual tumor cells form the nidus for local 
recurrences and delayed metastases, which are seen 
commonly in head and neck, prostate and other can-
cers. Not only does this profoundly impact patients’ 
overall survival, but also their quality of life, due to 
extensive treatment-related anatomic and functional 
alterations. The residual cancer cells at the surgical 
margins often show high resistance to local and sys-
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temic adjuvant chemotherapy and radiotherapy [1], 
thus requiring toxic levels of these treatments. This is 
of particular concern in head and neck squamous cell 
carcinoma (HNSCC), the sixth most common cancer 
diagnosis worldwide, with an estimated 263,000 
newly-diagnosed cases and over 128,000 deaths oc-
curring yearly [2]. Hence, there is a critical need to 
develop novel diagnostic and therapeutic modalities 
that not only complement current therapies to en-
hance tumor control, but also simultaneously limit the 
treatment-related morbidity that ensues from treat-
ment intensification, and can be applied as intra- or 
post-operative treatments. 
Recently introduced approaches have employed 
nanoparticles (NPs) and external energies to develop 
putative tumor-targeting capabilities through drug 
delivery [3-20], hyperthermia [21-31] and 
photodynamic therapy [31-33]. However, the prom-
ises of these new modalities did not provide their fast 
translation from the lab to the clinic for the following 
reasons: (i) low NP targeting specificity, (ii) tumor cell 
heterogeneity, (iii) resistance of phenotypes [1, 3, 4] 
and (iv) NP or energy-delivery toxicities [20-29, 
34-36]. Therefore, the development of novel technol-
ogies that will (a) selectively detect and eliminate 
drug-resistant residual cancer cells to prevent local 
and regional recurrence, (b) preserve the functionality 
of normal tissues and (c) reduce non-specific toxicity, 
is highly significant. In addition, an ability to unite 
both tumor detection and its treatment in one re-
al-time intra-operative theranostic procedure will 
improve the principal limitations of cancer surgery 
cited above. 
In order to overcome the limitations of the NP- 
and external energy-based medicine, we recently in-
troduced a new class of threshold-activated cellular 
nano-agents, called plasmonic nanobubbles (PNBs). A 
PNB is a laser pulse-induced nanoscale explosive 
event that develops only if the energy (fluence) of 
laser pulse exceeds specific threshold of the evapora-
tion of NP environment, a vapor nanobubble and not 
a NP, although it employs a gold NPs or their cluster 
to convert optical energy into heat for the evaporation 
of the liquid surrounding super-heated NP. The major 
difference that distinguishes PNBs from existing 
nano-agents is their on-demand threshold and tran-
sient nature, dynamic tunability and mechanical, not 
thermal, therapeutic mechanisms [37-40]. PNBs offer 
several unique oportunities that are not addressed by 
current methods (both traditional and those using 
various NPs and external energies). These are: (i) 
broad-spectrum efficacy against the major mecha-
nisms of drug resistance; (ii) selectivity due to efficient 
discrimination of cancer from normal cells and (iii) 
multi-functionality of diagnosis (through optical and 
acoustic signals [38, 39, 41]) and guided cell level 
therapeutics [37-40, 42].  
Based on the above, we hypothesized that the 
synergistic effect of PNBs coupled with low doses of 
traditional cytotoxic chemotherapies, gold NPs and 
optical energy would rapidly and selectively elimi-
nate drug-resistant micro-tumors in a single pulse 
treatment (Figure 1). We further hypothesized that the 
acoustic detection of PNB will provide simultaneous 
diagnostic tumor imaging and guidance of drug de-
livery (Figure 1). Utilizing models of HNSCC, we 
studied the in vitro and in vivo PNB generation, detec-
tion and intracellular delivery of encapsulated drug 
(Doxil) with the focus on providing high diagnostic 
and therapeutic efficacy and reducing non-specific 
therapeutic toxicity and the treatment time in a single 
theranostic procedure. 
 
 
 
Figure 1. (A): Separate administration of gold NP conjugates and encapsulated drug; (B): cancer cell self-assembles mixed clusters of the drug carriers and 
gold NPs during receptor-mediated endocytosis; (C): diagnostic function is provided by the selective generation of PNB around the cluster of gold NPs with 
a single laser pulse and remote real-time detection of the acoustic response of the PNB; single gold NPs in normal (green) cells have a higher threshold of 
PNB generation and thus do not produce a PNB under a low level of laser pulse fluence; (D): selective therapeutic effect is provided by explosive localized 
disruption of drug carrier and endosome by PNB and the ejection of the drug (blue dots) into cytoplasm. 
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MATERIALS AND METHODS 
PNB generation for drug delivery and diag-
nostics 
To overcome drug resistance of HNSCC and to 
reduce non-specific toxicity of anti-tumor drug we 
applied active and HNSCC cell-specific delivery of 
encapsulated doxorubicin (Doxil) into the cytoplasm 
of HNSCC cells in order to create a high local con-
centration of the drug. Instead of the existing passive 
diffusion-based mechanisms, we employ the 
PNB-induced localized, mechanical ejection of the 
drug from liposome and from endosomes (Figure 1D). 
This is achieved by generating small intracellular 
PNBs (non-invasive on their own), co-localized with 
drug liposomes in the complex intracellular clusters. 
The key to this method is in the separate administra-
tion of Doxil (Doxorubicin encapsulated into 85 nm 
liposomes) at significantly reduced doses and the 
conjugates of gold NPs with C225 antibody (Erbitux) 
(Figure 1A). Solid gold spheres of 20 nm and 60 nm 
diameter, the most available and FDA-approved gold 
NPs, were employed because they showed high PNB 
generation efficacy under near-infrared (780 nm) 
pulsed optical excitation (Figure 4C). Gold NPs and 
Doxil are non-toxic even when they are internalized 
by the cells, including their non-specific uptake by 
normal cells (Figure 1B). The therapeutic mechanism 
is provided by two steps: (i) cancer cells selectively 
self-assemble large, complex clusters of gold NPs 
co-localized with drug liposomes (Figure 1B) through 
receptor-mediated endocytosis (while normal cells 
cannot accumulate so many gold NPs and build clus-
ters of the same size as cancer cells); and (ii) the 
threshold generation of PNBs around gold NPs in 
these clusters with a single laser pulse at 780 nm, 70 ps 
(Figure 1C and D). Gold spheres efficiently generated 
PNBs with this short NIR laser pulse through our new 
method that employs the specific duration and low, 
safe fluence of the single laser pulse. These PNBs are 
small and therefore non-invasive alone [38, 40] (see 
also Figure 2C, 5D), but they simultaneously deliver 
two important functions. Their optical scattering and 
acoustic emission provide the remote and immediate 
detection of cancer cells (Figure 1C), and their me-
chanical, not thermal, impact immediately disrupts 
the liposome and endosome membranes and the 
pressure created by the expanding PNB ejects the 
drug into the cellular cytoplasm (Figure 1D). This fast 
(nanosecond) and localized (submicrometer) mecha-
nism creates a high local intracellular concentration of 
the drug that is impossible to achieve through con-
ventional slow delocalized diffusive processes of drug 
delivery. This overcomes most of the known mecha-
nisms of drug resistance and, in addition, allows the 
reduction of the initial dose of the drug to a level that 
does not cause non-specific toxicity.  
HNSCC models 
We used multi drug-resistant HN31 squamous 
carcinoma cells (associated with head and neck can-
cers) expressing epidermal growth factor receptor 
(EGFR) and immortalized normal human oral kerot-
inocyte NOM9 cells. The co-culture of HN31 and 
NOM9 cells was treated with 60 nm gold NP-C225 
conjugates using the clinically-validated C225 anti-
body against EGFR, the main molecular target in the 
treatment of HNSCC [43-45]. Cancer cells were iden-
tified among normal cells through the fluorescence of 
pre-transferred Green Fluorescent Protein (Figure 2).  
In vitro Doxil and NP-C225 conjugates were 
separately administered to cells during 24 hours 
(Figure 1A) and were then washed off prior to laser 
treatment. Thus the cells were exposed only to the 
internalized drug during the follow up generation of 
PNBs. The concentration of Doxil was varied from the 
therapeutic dose of 100 μg/ml [46] down to 1μg/ml. 
Uptake of NPs and Doxil by living cells was assayed 
with a confocal microscopy (LSM-710) in the bright 
field, optical scattering and two fluorescent modes.  
The in vivo model used mice with the same can-
cer cells. Tumors were xenografted with the HN31 cell 
lines as previously described [47]. All animals were 
monitored for tumor growth on a daily basis. When 
tumors reached 5-6 mm in diameter, gold NP-C225 
conjugates were administered locally (intra-tumoral 
injection of 1 μl at 9x1012 NP/mL (0.8 μg/g) and sys-
temically (intravenous injection in a tail vein of 200 μL 
at 4.5x1010 NP/mL (0.8 μg/g) at two diameters of 
NPs, 20 nm and 60 nm. Doxil was injected intra-
tumorally at three-fold reduced dose of 1 mg/kg rel-
ative to the therapeutic dose [46]. Twenty-four hours 
after the injection of gold NP-C225 conjugated and the 
drug, laser treatment of the animals was performed. 
The laser beam was scanned across the surface of the 
tumor and normal tissue at the speed of 1 mm2/s. The 
scan speed, beam diameter and pulse repetition rate 
(20 Hz) were synchronized in order to provide a sin-
gle pulse exposure mode for each area of the tumor 
and tissue. Each treatment mode was applied to 3-5 
animals. Animals were treated in accordance with the 
institutional guidelines and protocols of the Univer-
sity of Texas M. D. Anderson Cancer Center. 
Detection of PNBs 
PNBs were detected, imaged and measured 
through three independent methods that were em-
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ployed simultaneously (Supplementary Material: 
Figure S1). Optical scattering was employed in the 
two methods of time-response and time-resolved 
imaging. The duration of the optical scattering 
time-response was measured as the lifetime of the 
PNB. Time-resolved scattering images were used to 
image the location of PNBs in vitro. Acoustic detection 
employed the generation of the pressure transients 
during the PNB expansion and collapse, comple-
mented optical scattering detection, and, most im-
portantly for the diagnostic application, provided the 
in vivo detection of PNBs in opaque tissue. The am-
plitude of acoustic response was used as the PNB 
metric and was correlated to the optically measured 
lifetime of PNB (Supplementary Material: Figure S2F). 
Statistics  
Two-tailed t-tests were used to compare PNB 
lifetimes, cell death and necrosis levels from control 
groups and treatment groups. Statistical analyses 
were performed with Origin software (OriginPro8, 
OriginLab Corporation, Northampton, MA). p values 
< 0.05 were considered statistically significant. 
Other details of the experimental methods can be 
found in the Supplementary Material. 
RESULTS 
NP clustering and PNB generation and detec-
tion in cancer cells 
The mechanism of the formation of mixed gold 
NP-drug carrier clusters and on-demand generation 
of PNBs around such clusters was studied in a 
co-culture of drug-resistant HNSCC cells and normal 
cells.  
Selective formation of mixed intracellular clusters of 
gold NPs and Doxil. The NP clustering and 
co-localization with Doxil was analyzed with confocal 
microscopy in scattering (for gold NPs) and fluores-
cent (for Doxil that contains fluorescent doxorubicin) 
modes (Figure 2A). A co-culture of HN31 (HNSCC) 
and NOM9 (normal) cell was treated with C225 con-
jugates of solid gold 60 nm spheres and Doxil lipo-
somes. The antibody C225 (Erbitux) was clinically 
proven to target the Epidermal Growth Factor Re-
ceptor (EGFR) in HNSCC [43-45] and provided intra-
cellular clustering of gold NP-C225conjugates 
through the mechanism of EGFR-mediated endocyto-
sis [38, 48, 49]. Individual HN31 cells were identified 
through the fluorescence of the transfected Green 
Fluorescent Protein (Supplementary Material: Figure 
S2A). Analysis of the confocal images of cancer cells 
revealed complex clusters with gold NPs (blue in Fig-
ure 2A) co-localized with Doxil (red in Figure 2A). 
Adjacent normal cells also showed occasional NPs 
due to their non-specific accumulation, but no large 
NP-Doxil clusters were detected in normal cells (Fig-
ure 2A). Thus the complex large NP-Doxil clusters 
were selectively self-assembled only by cancer cells 
during the separate administration of Doxil and gold 
NPs. 
 
 
 
 
 
 
 
Figure 2. PNB-enhanced endosomal escape in vitro. (A): Confocal microscopy images of cancer (green boarder) and normal (adjacent) cells show NPs (blue) 
and Doxil (red) co-localized in the large mixed clusters (inset) only in cancer cell while adjacent normal cells show non-specific uptake of NPs and Doxil 
(scale bar is 5 μm); (B): time-resolved optical scattering image of the same sample shows PNBs selectively generated with a broad single laser pulse (780 
nm, 70 ps, 40 mJ/cm2) only in cancer cell and their co-localization with NP-Doxil clusters; (C): PNB lifetime (blue bars) and cell death level (red bars) 
measured in 72 h after laser treatment for cancer (solid bars) and normal (hollow bars) cells after the application of several treatment modes (PNB+D: single 
laser pulse, NPs and Doxil, PNB: single laser pulse and NPs; NP+D: NPs and Doxil (* p < 0.001, ** p<0.05, *** p > 0.05); D: Doxil, intact: non-treated cells); 
(D): DL50 dose for cancer cells as function of drug dose and PNB lifetime.  
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Generation and detection of PNBs in individual cells. 
We next determined the conditions of the PNB gen-
eration in the complex NP-Doxil clusters in cells. 
PNBs were generated by exposing the co-culture of 
HN31 and NOM9 cells to single near-infrared laser 
pulses (70 ps, 780 nm) of broad diameter (that pro-
vided the simultaneous irradiation of cancer and 
normal cells) and varying laser fluence (the energy 
per unit of square) in the range of 10-100 mJ/cm2 
(Supplementary Material: Figure S1). In this work we 
applied for the first time the safest combination of 
FDA-approved solid gold spheres and near-infrared 
laser radiation in a low dose that provides the deepest 
tissue penetration and the minimal bio-damage [50]. 
Optical scattering time-resolved imaging (Figure 2B 
and Supplementary Material: Figure S2) and optical 
scattering time-responses (Supplementary Material: 
Figure S2) were obtained for individual cancer and 
normal cells simultaneously with the excitation laser 
pulses and were employed to image and quantify 
PNBs in the irradiated cells.  
Both images (Figure 2B and Supplementary 
Material: Figure S2) and time-responses (Supplemen-
tary Material: Figure S2) showed the cancer 
cell-specific generation of PNBs while normal 
by-stander cells in the co-culture produced no or very 
small PNBs in a wide range of laser pulse fluences 
(Figure 2B and Supplementary Material: Figure S2E). 
This demonstrated the selectivity of the clus-
ter-threshold mechanism of PNB generation. The 
comparison of the optical scattering images of PNBs 
(Figure 2B) and NP-Doxil clusters (Figure 2A) re-
vealed their good co-localization in cells. Thus the 
mixed NP-Doxil clusters acted as PNB sources and the 
mechanical impact of PNBs was co-localized to Doxil 
liposomes. In this experiment PNBs provided optical 
detection of cancer cells with high specificity and 
sensitivity. 
The mechanism of drug delivery with PNBs 
The mechanism of intracellular delivery and 
on-demand release of an encapsulated drug (doxoru-
bicin in Doxil liposomes) was studied in the same 
co-culture of HN31 and NOM9 cells.  
Therapeutic effect of PNBs in vitro was measured 72 
hours after a single pulse laser treatment as the level 
of cancer cell death in several different treatment 
modes (Figure 2C). We correlated the size of PNBs 
(measured by their lifetimes, obtained as the duration 
of time-responses of individual cells, Supplementary 
Material: Figure S2) to their therapeutic effect. Rela-
tively small PNBs of 20-90 ns lifetime showed the low 
therapeutic efficacy (low death level for cancer cells) 
and the low non-specific toxicity (low death level for 
normal cells) when used alone (Figure 2C). Earlier we 
found that only large PNBs with a lifetime > 130 ns 
mechanically kill the cells [38, 39].  
Synergistic effect of PNB and Doxil. Direct exposure 
of cells to Doxil and gold NPs without laser pulses 
had a limited effect on cancer cells due to their drug 
resistance coupled with a relatively low dose of Doxil 
(5 μg/ml, 20-fold lower than the effective therapeutic 
dose [46]). Such a low dose of the drug reduced 
non-specific toxicity, as we observed minimal damage 
to normal cells (Figure 2C). However, when PNBs 
were generated in the mixed NP-Doxil clusters, the 
cell death level increased by 30-fold among cancer 
cells (relative to the drug alone mode) but remained 
relatively low among normal cells where no PNBs 
were generated (Figure 2C). A quantitative analysis of 
the DL50 doses (the doses that caused 50% cell death 
level) for cancer cells as a function of the Doxil dose 
and PNB lifetime revealed the synergistic effect of the 
joint action of PNBs and Doxil (Figure 2D). The opti-
mal PNB-Doxil combination corresponded to 
non-invasive PNBs of 51±7 ns lifetime (when used 
alone without the drug) and non-toxic doses of Doxil 
of 3 μg/ml (when used alone without the PNB).  
This selective and efficient therapeutic effect was 
achieved due to the localized, active, mechanical re-
lease (ejection) of the drug from liposomes and en-
dosomes (Figure 1D) that were disrupted by an ex-
panding co-localized PNB. This process took tens of 
nanoseconds and required a single laser pulse of a 
low dose to provide the selective intracellular release 
of the drug only in cancer cells. We termed this 
mechanism, a PNB-enhanced endosome escape. 
Normal cells did not develop PNBs under identical 
laser and NP treatment and thus the Doxil liposomes 
non-specifically taken by normal cells (Figure 2A) 
were not disrupted by PNBs and did not release the 
drug (Figure 2C). Unique to this technology, PNBs 
provided the optical detection of cancer cells and their 
selective destruction in a single, fast theranostic pro-
cedure.  
NP targeting, PNB generation and detection in 
HNSCC tumor in vivo 
In order to translate the achieved result in vivo 
and to address the impact of tissue on the propagation 
of light and NPs, we first studied the delivery of NPs, 
laser radiation and the generation and detection of 
PNBs in a xenograft mouse model of HNSCC that 
used the same cancer cell line, HN31. 
NP delivery and clustering in vivo. The formation 
of NP clusters in the tumor was imaged and quanti-
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fied by using TEM microscopy and the PNB genera-
tion in the tumor slices. NP-C225 conjugates of solid 
gold 60 nm spheres were administered locally (in-
tra-tumoral injection of 1 μl at 9x1012 NP/mL (0.8 
μg/g) and systemically (intravenous injection in a tail 
vein of 200 μL at 4.5x1010 NP/mL (0.8 μg/g) at two 
diameters of NPs, 20 nm and 60 nm. In 24 hours after 
systemic administering 60 nm gold NP-C225, TEM 
analysis of the tumor and adjacent normal muscle 
tissue showed large clusters of gold NPs (an average 
size 297±135 nm) only in the tumor (Figure 3A) while 
non-specific uptake resulted in occasional single NPs 
in normal tissue (an average size close to that of a 
single NP, 64±15 nm, Figure 3B). Thus, despite a 
non-specific uptake of single gold NPs by normal 
tissues the sources of PNBs, larger NP clusters, were 
observed only in tumors and not in normal tissues. 
Selectivity of PNB generation in tumor. Next, gold 
NP clusters were analyzed as PNB sources in tumor 
slices. Each individual cell in a slice was identically 
exposed to a single laser pulse and the PNB lifetimes 
were obtained for cancer (fluorescently-identified) 
and normal cells in a similar way to the above in vitro 
experiment (Supplementary Material: Figure S2C). At 
the fluence of 40 mJ/cm2 single pulse excitation re-
sulted in the generation of PNBs only in cancer cells 
while normal cells did not generate PNBs under such 
a low fluence level (Figure 3C). This result indicated 
that tumor-specific gold NP clusters (not present in 
normal cells and tissues) provided selective genera-
tion of PNBs only in tumor cells. The mechanism of 
such high selectivity is based on the dependence of 
the PNB generation threshold upon the size of the NP 
or its cluster: the threshold fluence decreases with the 
cluster size [41, 42, 49, 62].The level of laser pulse 
fluence applied was below the PNB generation 
threshold for single NPs but above the PNB genera-
tion threshold for large NP clusters. These results 
correlated well to those obtained previously in vitro 
(compare Figure 3C to Figure 2C) and demonstrated 
selective formation of NP clusters and PNB genera-
tion only in tumor while the non-specifically taken 
gold NPs in normal tissue did not form clusters and 
therefore were unable to generate PNBs. 
Detection of PNBs in vivo in opaque tissue. Due to 
the limited optical transparence of real tissue in ani-
mals we replaced the optical detection of PNBs with 
the acoustic method (Figure 4A). Briefly, the expan-
sion and collapse of a PNB produces pressure pulses 
(Figure 1C, red) that can be remotely detected in 
opaque tissue in animals with an ultrasound detector 
as PNB-specific acoustic time-responses (Figure 4B). 
The amplitude of the acoustic response of a PNB was 
found to be almost linearly proportional to the opti-
cally measured lifetime of the same PNB (Supple-
mentary Material: Figure S2F). Thus we employed the 
acoustic signal amplitude as an in vivo metric of PNB.  
Near-infrared pulsed excitation of PNBs in tumor. 
Next, in order to optimize the laser wavelength for the 
near-infrared excitation the acoustic amplitudes of 
PNBs were obtained as the spectra of the excitation 
laser wavelength in tumor and normal tissue in ani-
mals that received intravenous gold NP-C225 conju-
gates and for a intact tumor in animals that did not 
receive any gold NPs (Figure 4C). Spectrum of the 
tumor in the NP-treated animal showed a 3 nm wide 
peak at 780 nm. Other NIR wavelengths returned 
much lower signals comparable to the background 
level. The normal tissue of the NP-treated animal 
showed very small acoustic signals that were also 
comparable to the background level, while intact tu-
mor returned zero signals under identical optical ex-
citation (Figure 4C). We concluded that the detected 
acoustic signals of the NP-treated tumor were associ-
ated with gold NP clusters that were selectively 
formed in the tumor cells as we found previously 
(Figure 3A). We therefore employed the near-infrared 
wavelength of 780 nm for the experiments in vivo. 
 
 
Figure 3. NP-C225, solid gold 60 nm spheres conjugates in HNSCC-bearing mouse: transmission electron microscopy image of a tumor (A) and adjacent 
muscle tissue (B) in 24 h after systemic injection of NP-C225 to mouse. (C): Histogram of the PNB lifetime obtained for individual cells in slices of tumor 
for cancer (green) and normal (grey) cells after being extracted from mice in 24 hours after systemic administering of NP-C225. 
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Figure 4. PNBs in HNSCC-bearing mouse. (A): Functional diagram of the experimental set up, optical fiber delivers short laser pulse through the surface 
of the tissue, PNBs are detected with ultrasound detector, which signals, the scan of the fiber and laser pulse generation are controlled by computer 
program; (B): acoustic responses to single laser pulses (70ps, 780 nm, 40 mJ/cm2) obtained from a tumor (green) and adjacent muscle (black) in mouse 
systemically treated with 60 nm solid gold sphere conjugates, NP-C225; (C): Spectrum of PNB amplitudes of acoustic responses obtained from a squamous 
cell carcinoma tumor (solid green) and normal tissue (hollow black circles) of a mouse systemically treated with C225-conjugated 60 nm gold spheres, tumor 
in intact animal (solid black squares) and (40 mJ/cm2 ); (D): Ddependence of the amplitudes of acoustic responses upon laser pulse fluence (energy per square 
unit) for the same animals obtained from the tumor (green) and adjacent muscle (black) (* p < 0.001); (E): acoustic amplitudes obtained during the scans of 
the tumor, muscle and blood of NP-treated animals and of a tumor of an intact animal (* p < 0.001); (F): dependence of PNB lifetime (blue, optical response 
obtained from individual tumor cells in vitro) and the acoustic amplitude of PNB (green, acoustic response obtained from a tumor in animal) as function of 
NP size (20 nm and 60 nm) and in vivo administration route (local intra-tumor injection and intra-venous injection) under identical laser excitation (single 
pulse,70 ps,780 nm, 40 mJ/cm2). 
 
Real-time detection of the tumor with acoustic signals 
of PNBs. The specificity and sensitivity of the tumor 
detection were studied through the amplitude of 
acoustic signal of PNBs that was measured as function 
of tissue type and of the laser excitation fluence. The 
amplitude of PNB signal increased with the fluence of 
the excitation laser pulse (Figure 4D). It should be 
noted that just a single laser pulse was required to 
detect a tumor-specific acoustic signal. The duration 
of this diagnostic process was limited by the speed of 
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the ultrasound detector and was below one millisec-
ond. 
During the laser scans of a tumor and normal 
adjacent tissue in the NP-treated animals, the detect-
able acoustic signal of the PNBs was observed only for 
the tumor and not for normal muscle tissue and blood 
(Figure 4D). Tumors in intact animals (that did not 
receive gold NPs) did not yield any detectable acous-
tic signal under the identical fluence of laser pulse 
(Figure 4D). Therefore, the optical fluence of 40 
mJ/cm2 was below the bubble generation threshold in 
blood and other normal tissues for the employed NIR 
wavelength (780 nm) and duration (70 ps) of laser 
pulse. The results demonstrated high sensitivity, 
specificity, safety and speed of tumor detection in a 
single near-infrared laser pulse procedure. 
Optimization of the NP size and delivery route for 
PNB generation in vivo. In addition, we analyzed the 
influence of the NP diameter and delivery route on 
PNBs generation in vitro and in vivo. The intravenous 
systemic delivery of NPs resulted in larger PNBs 
compared to local intra-tumor injection of the same 
NPs under identical optical excitation (Figure 4E). In 
both cases the NP-C225 conjugates were administered 
24 hour prior to the laser treatment. Larger 60 nm NPs 
generated larger PNBs compared to smaller 20 nm 
NPs both in vivo and in vitro conditions (Figure 4F). 
We therefore used systemic intravenous delivery of 
solid gold 60 nm sphere conjugates, NP-C225, for the 
next, therapeutic stage.  
PNB therapeutics of HNSCC tumor in vivo 
The therapeutic mode of PNBs employed both 
the above methods of generation and detection of 
PNBs in vivo and of PNB-enhanced endosome escape 
intracellular delivery of the encapsulated drug. We 
next determined the therapeutic efficacy of tu-
mor-targeted PNBs and Doxil in a mouse model of 
HNSCC.  
In vivo administration of NPs, Doxil and laser radia-
tion for cancer therapeutics. We separately administered 
Doxil- and gold 60 nm NP-C225 conjugates to an 
HNSCC bearing mouse. Doxil was administered lo-
cally at the concentration of 1mg/kg, 3-fold lower 
than therapeutic concentration [46]. NP-C225 conju-
gates were administered intravenously simultane-
ously with Doxil at the concentration of 4.5x1010 
NP/mL (200 μl). After 24 hours, one-half of the tumor 
and the adjacent normal tissue were scanned with 
single laser pulses at 20Hz while the intact part of the 
tumor was used as the non-irradiated control. We 
applied the single laser pulse irradiation with the 
same parameters as those established earlier in vitro, 
780 nm, 70 ps, 40 mJ/cm2, and increased the laser 
beam diameter to 0.25 mm in order to improve the 
tissue penetration depth [50]. The part of animal sur-
face with the tumor and normal tissue was scanned 
with the laser beam at the rate 1 mm2/s. Real-time 
acoustic monitoring showed the PNB signals of 36± 3 
mV amplitude for the tumor (Figure 5D) and 0 mV for 
the adjacent muscle tissue. This result approximated 
the previous in vivo diagnostic experiment (Figure 4B 
and D) and confirmed the tumor-specific generation 
of PNBs in therapeutic mode. 
Therapeutic effects of PNBs and Doxil. Next, we 
analyzed the effect of several treatment combinations 
for tumor and for adjacent normal muscle tissue: (i) 
single laser pulse + NP + Doxil, (ii) single laser pulse + 
NP (PNBs alone, similar to the diagnostic mode), (iii) 
NP + Doxil (evaluation of the toxicity of NPs and 
drug), (iv) Doxil (analog of standard chemotherapy at 
the reduced dose) and (v) intact tumor or muscle. 
After 72 hours, the tumor and normal tissue were 
harvested and the relative level of necrosis was ana-
lyzed with a standard histopathological technique 
(see Supplementary Material). The analysis of the 
level of necrosis in the tumor (Figure 5A-C) showed a 
high damage zone only for the combination laser 
pulse + NP + Doxil (Figure 5A and D) that was asso-
ciated with the generation of small PNBs. This result 
corresponded to in vitro case of the co-localized PNBs 
and Doxil (Figure 2C). The therapeutic effects of the 
PNBs or Doxil alone were low, less than 7% each 
(Figure 5B and D), meaning that only small 
non-invasive PNBs were generated. This non-invasive 
nature of PNBs alone was in line with the corre-
sponding in vitro results that also showed low 
PNB-induced cell death (Figure 2C). The toxic effect of 
NPs was also low (Figure 5C and D). Therefore, the 
single low dose of Doxil applied coupled with the 
drug resistant nature of the HNSCC tumor resulted in 
the low therapeutic efficacy. In contrast, the joint ac-
tion of PNBs and Doxil resulted in the synergistic 
enhancement of the necrosis level up to 80-92%, while 
the additive effects of PNBs alone and Doxil alone did 
not exceed the necrosis level of 13% (Figure 5D). This 
demonstrates how PNB-enhanced endosomal escape 
mechanism overcomes the drug resistance of HNSCC 
even under the low dose of the drug. In addition, the 
level of necrosis correlated well to the acoustic am-
plitude of PNBs in drug-treated animals (Figure 5D) 
thus allowing the real-time guidance of the therapeu-
tic efficacy of PNBs during the laser scan.  
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Figure 5. PNB therapeutics of HNSCC tumor in mouse. Tumor depth profiles in (A-C) show tumor (green) and necrotic tumor (yellow) for the treatment 
modes: (A, E, solid red): PNB+D: small PNBs (40 mJ/cm2 @780 nm, 70 ps, single pulse, NP: gold 60 nm spheres conjugated to C225) and Doxil (1 mg/kg); 
(B, E, hollow red): PNBs alone; (C, E, hollow black): Doxil+NP; (D): Level of necrosis (red bars) at 0.3 mm depth and acoustic signals of PNBs (green bars) for 
the listed treatment modes (p < 0.001, ** p > 0.05). (E): Dependence of the level of necrosis in tumor upon tissue depth (PNB+D: solid red, PNB: hollow red, 
NP+D: hollow black, D: magenta, intact tumor: blue). 
 
Correlation of in vitro and in vivo results and the 
PNB therapeutic mechanism. A comparison of the cor-
responding treatment modes in vivo and in vitro (Fig-
ure 2C vs Figure 5D) demonstrated the high similarity 
of the therapeutic effects in both models, thus con-
firming the earlier established therapeutic mechanism 
of PNB-enhanced endosomal escape of the drug from 
liposomes and endosomes (Figure 1D). Regardless of 
the mechanism of drug resistance, the cancer cell 
failed to protect itself from the mechanical explosive 
action of PNBs that ejected the drug into cellular cy-
toplasm. The nanosecond speed of this process was 
much higher than traditional diffusion-based release 
processes. Such fast release of the drug resulted in its 
high local intracellular concentration that was suffi-
cient to kill drug-resistant cells after a single admin-
istration of a 3-fold reduced dose of Doxil. This, in 
turn, reduced the treatment time from up to a week 
[46] to less than 1 minute of laser scan.  
Reduction of non-specific toxicity. As a result of the 
reduction in the drug, NP and optical doses, we ob-
served very low non-specific toxicity. The levels of 
necrosis in normal tissue under an identical treatment 
combination (NP-C225 + Doxil + single laser pulse) 
were found to be 0 %, even despite non-specific up-
take of NPs and the drug by normal cells and tissues. 
The threshold mechanism of PNBs prevented their 
generation in normal tissue (Figure 4C-E) and thus 
prevented the non-specific release of the drug in 
normal tissue. This demonstrated the high safety and 
selectivity of PNB therapeutics (see also the Discus-
sion).  
Penetration depth of the PNB treatment. In order to 
study the effect of the optical attenuation by the tumor 
we measured the level of necrosis level as a function 
of the tissue depth for all treatment modes (Figure 
5E). The laser-NP-Doxil mode demonstrated high 
therapeutic efficacy (70-92%), up to 1.5-1.8 mm depth 
for the laser beam of 0.25 mm diameter. This was 
achieved by using the near-infrared wavelength (780 
nm) that previously was shown to provide the max-
imal penetration depth and minimal phototoxicity on 
a tissue [50]. Since the penetration depth of laser ra-
diation increases with the diameter of the laser beam 
[50] this parameter can be further improved by using 
broader laser beam. 
To summarize the therapeutic studies in vivo, the 
application of small non-invasive PNBs for intracel-
lular release of the low doses of encapsulated drug 
allowed us to overcome drug resistance and to reduce 
non-specific toxicity and treatment time.  
DISCUSSION  
Mechanism of PNB therapeutics versus cur-
rent therapeutic mechanisms  
Our results demonstrated simultaneous ability 
of PNBs to deliver high sensitive diagnosis and selec-
tive, efficient and localized therapeutics in a single 
laser pulse theranostic procedure. The therapeutic 
mechanism of PNBs is based on active intracellular 
drug delivery through rapid mechanical, non thermal, 
disruption of drug carriers and endosomes and local-
ized ejection of drug into cytoplasm (Figure 1D). This 
mechanism is distinct from the existing drug delivery 
mechanisms that are slow or non-specific. Current 
approaches for in vivo drug delivery, direct or en-
hanced by hyperthermia or photodynamic therapy 
employ various NPs [3, 8, 9, 13, 14], external energies 
[15, 17, 18, 26-31] or their combinations [11, 12, 20, 21, 
26, 31-33]. However, their efficacy is limited by the 
slow diffusive nature of the drug release, while 
non-specific uptake of NPs or the non-specific nature 
of the external energy-stimulated release increase re-
quired doses of drugs and NPs and cause significant 
non-specific toxicity.  
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There are also well-established delivery methods 
that employ cavitation bubbles as ultrasound- or op-
tically-induced events [17, 18, 34-36, 51, 52] or nano-
bubbles as particles [53-58]. Similar to the previously 
discussed methods, these “bubble” methods have a 
non-specific release mechanism, generate large bub-
bles that cannot discriminate cancer from normal cells 
and increase non-specific toxicity. Furthermore, an 
ultrasound cannot be applied as a single short (< 1 
ms) pulse.  
In contrast, PNBs reduced the NP dose by 2-4 
orders of magnitude compared to the photothermal 
therapies [21, 25, 27, 28, 30, 31] optical energy dose by 
101-4 fold compared to photothermal drug delivery 
[11, 12] and photodynamic therapies [31-33] and drug 
dose by > 3 fold compared to standard chemotherapy 
[46]. Most of all, PNBs provided a single cell selectiv-
ity of the therapeutics and spared even adjacent nor-
mal cells.  
Mechanism of PNB diagnostics versus current 
diagnostic mechanisms 
The diagnostic part of PNB theranostics is tech-
nically close to photoacoustic methods [59], but PNBs 
provide higher sensitivity and specificity of tumor 
detection compared to broadly used gold NPs as 
photoacoustic probes. Conventional photoacoustics 
employs acoustic emission from all NPs, instead of 
cancer cell-specific generation of PNBs only around 
NP clusters (Figure 1C) as can be seen by comparing 
Figure 3 and Figure 4B. Under identical optical exci-
tation, PNBs emit stronger pressure pulses compared 
to those emitted by gold NPs [60]. This explains the 
high specificity of PNB signals as shown in Figure 4B 
and Figure 4C and the high sensitivity that allows to 
detect even single tumor cells among normal ones 
[38]. Thus the PNB method provided high sensitivity, 
specificity and speed of tumor detection in a single 
near-infrared laser pulse procedure under relatively 
low optical fluence of 40 mJ/cm2, which is within the 
medical safety limits for laser radiation [61] and with 
the safest solid gold spheres. 
Advantages of using PNBs as transient events 
instead of nano-materials with pre-determined 
properties 
The results reported above were achieved due to 
the novel biophysical properties of PNB’s: (i) explo-
sive nano-event whose mechanical, not thermal, ac-
tion rapidly creates a high intracellular concentration 
of the released drug (Figure 1); (ii) ability to scatter the 
light and to emit a pressure pulse makes it a sensitive 
cellular diagnostic probe [38, 62]; (iii) the clus-
ter-threshold mechanism of PNBs overcomes 
non-specific uptake of gold NPs by normal cells be-
cause the PNB generation threshold is minimal for 
large clusters of NPs self-assembled by cancer cells 
[38, 40, 62]; (iv) a single NP cluster of 5-50 NPs per cell 
and a single laser pulse are sufficient for detecting and 
elimination the cancer cells with single PNB thus 
substantially reducing the NP and laser energy doses; 
(v) therapeutic and diagnostic functions of PNBs can 
be activated simultaneously in a single pulse proce-
dure [39, 63]; (vi) a PNB can be generated with 
FDA-approved gold spheres and a single 
near-infrared laser pulse of low dose and the maximal 
tissue penetration depth [50], thus eliminating the 
need in specially-engineered near-infrared NPs (such 
as nanorods and other NPs) and in prolonged optical 
excitation.  
Translational potential of PNBs 
The major limitations of the PNB method are 
associated with the limited penetration of light and 
gold NPs into heterogeneous tumors and with pho-
totoxicity. The energy of commercial lasers allows an 
increase in the diameter of the laser beam of up to 3-4 
mm and thus to achieve 5-7 mm range of tissue depth 
[50] and 100 mm2/s scan speed. Both metrics match 
the needs of intra-operative treatment of residual 
disease. The optical dose if near-infrared laser radia-
tion required for PNB generation is relatively low 
10-40 mJ/cm2, 4-6 orders of magnitude lower than 
those employed in previously reported in vivo studies 
of photothermal hyperthermia with gold NPs (3 - 72 
x102 J/cm2) [11, 12, 25, 27, 28]. Such a reduction in op-
tical dose was achieved by using a single pulse of low 
fluence instead of prolonged, continuous irradiation. 
In our method, the optical dose becomes equal to the 
pulse fluence and is comparable to the established 
laser safety limits of 30-50 mJ/cm2 for pulsed laser 
radiation [46]. Using off-resonant near-infrared exci-
tation of FDA-approved solid gold spheres reduces 
the laser-induced NP temperature and, therefore, the 
thermal damage to NPs and to surrounding tissues. 
The combination of the efficacy, cell selectivity, safety, 
single pulse speed and multi-functionality of PNB 
theranostics demonstrated in our experiments have 
not been achieved to date in vivo with any current 
technologies. This all demonstrates translational po-
tential of PNBs for the intra-operative treatment of 
surgical bed for monitoring and eliminating residual 
disease in real time.  
CONCLUSIONS 
We demonstrated for the first time in vivo the 
novel concept of PNB theranostics that enables diag-
nosis through the acoustic detection of the PNBs and 
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the simultaneous efficient treatment of drug-resistant 
tumors through the PNB-enhanced endosomal escape 
mechanism of intracellular drug delivery in a single 
laser pulse procedure: 
1. The tumor-preferred clustering of gold nano-
particle conjugates, coupled with the threshold 
mechanism of PNB generation provided the cell level 
specificity of tumor detection and elimination.  
2. Plasmonic nanobubbles increased the thera-
peutic efficacy of the standard drug by more than 
10-fold compared to chemotherapy alone (Doxil @ 1 
mg/kg), and eliminated > 80% of the drug-resistant 
HNSCC tumor within 1 mm of tissue depth in a fast 
single treatment. 
3. Cumulated non-specific toxicity of the drug, 
gold nanoparticles and laser radiation was reduced 
below a detectable level. 
4. The treatment time was reduced to less than 
one min for a tumor of five mm size by non-invasively 
scanning single near-infrared laser pulses (780 nm, 70 
ps) at the safe optical dose of 40 mJ/cm2. 
By using the safest and commercially available 
gold NPs, solid spheres, a low dose of near-infrared 
single laser pulse and standard encapsulated drugs 
(not linked to NPs), PNB technology can be applied 
for local and real-time adjuvant treatment of poor-
ly-detectable and curable residual drug-resistant mi-
cro-tumors during or immediately after surgery. The 
universal mechanism of PNB technology allows its 
extension to many cancers and other pathologies that 
require precise local treatment and thus may com-
plement existing surgical and chemotherapeutic ap-
proaches. 
SUPPLEMENTARY MATERIAL 
Supplementary Methods, Fig.S1-S3. 
http://www.thno.org/v02p0976s1.pdf 
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